Aditxt Signs Share Exchange Agreement to Acquire AiPharma Global Holdings

Aditxt Acquires Appili Therapeutics

October 10, 2024

Healthcare Services

Aditxt, Inc. announced that Appili Therapeutics shareholders will vote on a proposed acquisition of all issued and outstanding shares of Appili through a plan of arrangement. Appili’s board recommended shareholders vote in favor, and Aditxt intends to use Appili’s infectious disease pipeline (including the FDA-approved LIKMEZ) to expand its reach in combating life-threatening infections and biodefense threats.

Aditxt Signs Asset Purchase Agreement for 50% Ownership of Global Response Aid (Avigan) with Cellvera and Agility

April 20, 2023

Pharmaceuticals

Aditxt, Inc. signed an asset purchase agreement to acquire 50% ownership of Global Response Aid FZE (GRA), with the other 50% owned by Agility, Inc. The transaction includes $24.5 million consideration (including forgiveness of a $14.5 million loan and $10 million cash) plus future royalties for seven years, granting Aditxt rights to manufacture and market the broad-spectrum antiviral Avigan 200mg worldwide excluding Japan, China, and Russia.

BiomX Acquires Adaptive Phage Therapeutics

March 18, 2024

Biotechnology

BiomX Inc. completed a stock-for-stock acquisition of Adaptive Phage Therapeutics (APT), making APT a wholly owned subsidiary and combining phage therapy capabilities and pipelines. Concurrently, BiomX raised $50 million in a private placement led by affiliates of Deerfield Management and the AMR Action Fund to advance two Phase 2 assets (BX004 and BX211) toward pivotal readouts in 2025–2026.

Aditxt Enters Revenue-Sharing Agreement with Cellvera in Connection with Proposed Acquisition of Cellvera

April 5, 2022

Biotechnology

Aditxt, Inc. has entered into a revenue-sharing agreement with Cellvera Global Holdings LLC and certain affiliates to support Aditxt’s proposed acquisition of Cellvera. The agreement provides Aditxt with up to 10% of net sales (up to $30 million) while enhancing the security for Cellvera’s loan to Aditxt and extending the due diligence period for the overall transaction.

Aditxt, Inc. to Acquire Evofem Biosciences, Inc. to Build a Global Women’s Health Platform

December 12, 2023

Healthcare Services

Aditxt, Inc. (NASDAQ: ADTX) signed a definitive agreement to acquire Evofem Biosciences, Inc. (OTCQB: EVFM) in a transaction with an aggregate value of approximately $100 million, using a mix of Aditxt common and preferred stock plus assumption of certain senior indebtedness. The deal is intended to create a women’s health mission within Aditxt and position Evofem’s Phexxi and other products for global expansion.

Aditxt, Inc. (via Adifem, Inc.) to Merge with Evofem Biosciences, Inc.

November 6, 2024

Healthcare Services

Evofem Biosciences announced it has secured voting agreements from certain Series E-1 stockholders and convertible noteholders to approve its proposed merger with Aditxt’s subsidiary, Adifem, Inc., under an amended and restated merger agreement. The deal would result in Evofem merging into and becoming a wholly owned subsidiary of Aditxt (with the surviving entity described as Evofem). Closing is subject to conditions including stockholder approval and Aditxt raising sufficient capital for approximately $17 million in cash payments (including funding a senior secured noteholder).